Marina Biotech, a nucleic acid-based drug discovery and development company focused on rare diseases, and Turing Pharmaceuticals have executed a term sheet under which Marina intends to acquire Turing’s intranasal ketamine program. Pending the negotiation of the definitive agreement, Marina is expected to acquire Turing’s intranasal ketamine program for approximately 53 million Marina common shares. The assets to be acquired will include all patents and intellectual property right...